drugset
drugset / Trial / NCT04091932

Treatment of PD-1 Inhibitor in AIDS-associated PML

NCT04091932 ↗

Phase 2 Unknown 10 enrolled First Affiliated Hospital of Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

PD-1 inhibitor （Pembrolizumab, 2mg/kg weight, once per 4 weeks and 3 times of medication usage）treatment on AIDS patients with progressive multifocal leukoencephalopathy.

Timeline

Start
2019-08-20
Primary completion
2020-02
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 2 mg/kg —

Indications

AIDS progressive multifocal leukoencephalopathy